Hovione Ventures Ltd

Hovione Ventures Limited is a Cork‑based, healthcare‑specialised investment firm that backs early‑stage life‑science and biotechnology companies across Europe. Building on the legacy of its Bionova Capital subsidiary – which from 2015 to 2024 funded pioneering start‑ups and achieved two profitable exits, including the landmark CellmAbs deal – Hovione Ventures now channels its expertise through Biovance Capital Partners, the newly‑launched venture‑capital arm.

The core service offered is strategic equity financing, with the Biovance Capital Fund I providing up to €60 million to nurture innovative biotech enterprises from concept to commercialisation. By combining capital with deep sector knowledge, the firm supports founders in accelerating research, scaling operations and navigating regulatory pathways. Recent milestones illustrate the impact of this approach: BioNTech’s acquisition of CellmAbs technology, the launch of Biovance Capital Partners, and a €750,000 funding round for portfolio company Delox.

Hovione Ventures serves visionary entrepreneurs and emerging biotech firms seeking both financial backing and seasoned guidance to bring breakthrough healthcare solutions to market.